Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BGB-11417 |
| Synonyms | |
| Therapy Description |
BGB-11417 selectively inhibits Bcl2, which potentially leads to decreased tumor cell proliferation and inhibition of tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 3077). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BGB-11417 | BGB 11417|BGB11417|Sonrotoclax | BCL2 inhibitor 27 | BGB-11417 selectively inhibits Bcl2, which potentially leads to decreased tumor cell proliferation and inhibition of tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 3077). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05952037 | Phase II | BGB-11417 | Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenstrom's Macroglobulinemia | Recruiting | USA | ITA | GBR | FRA | ESP | AUS | 1 |
| NCT05471843 | Phase II | BGB-11417 | Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma | Active, not recruiting | USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | DEU | BRA | BEL | ARG | 2 |
| NCT04277637 | Phase I | BGB-11417 + Zanubrutinib BGB-11417 | Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies | Recruiting | USA | NZL | ITA | GBR | ESP | DEU | AUS | 0 |
CKB BOOST